NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), announced today that its PGxHealth™ division, provider of Therapeutic Diagnostics™, has launched a new test, PGxPredict:CLOZAPINE™, a pharmacogenetic test designed to aid physicians prescribing or considering prescribing clozapine. This is the first of several tests that Clinical Data intends to release this year, again demonstrating its ability to develop, validate and commercialize proprietary, pharmacogenetic tests in the ever-evolving field of pharmacogenetics.
